Sanj K. Patel - 04 Mar 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
04 Mar 2024
Net transactions value
-$391,056
Form type
4
Filing time
06 Mar 2024, 17:37:37 UTC
Previous filing
06 Sep 2023
Next filing
11 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Sale $200,442 -9,406 -11% $21.31 73,930 04 Mar 2024 Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 F1, F2
transaction KNSA Class A Common Share Sale $73,392 -3,336 -4.5% $22.00 70,594 04 Mar 2024 Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 F1
transaction KNSA Class A Common Share Sale $117,222 -5,582 -7.9% $21.00 65,012 06 Mar 2024 Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 F1
holding KNSA Class A Common Share 109,795 04 Mar 2024 Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016
holding KNSA Class A Common Share 52,516 04 Mar 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.00 and $21.785. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.